Patients alive at 5 years
In the combined PD-L1 ≥ 1% and < 1% population, 47 Japanese patients were alive at 5 years (nivolumab plus ipilimumab: PFS in Japanese patients alive at 5 years (PD-L1 ≥ 1% and < 1%). At the 5-year cut-off, 59% (95% CI, 39%–75%) of patients in the nivolumab plus ipilimumab arm versus 15% (95% CI, 4%–34%) in the chemotherapy arm were off treatment without receiving any subsequent therapy (Table 